Eminase (Wulfing Pharma GmbH): Full Drug Profile
Eminase (Wulfing Pharma GmbH) - General Information
Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.
Pharmacology of Eminase (Wulfing Pharma GmbH)
Eminase (Wulfing Pharma GmbH) cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Additional information about Eminase (Wulfing Pharma GmbH)
Eminase (Wulfing Pharma GmbH) Indication: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction Mechanism Of Action: Eminase (Wulfing Pharma GmbH) cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Anistreplase Synonyms: Tissue-type plasminogen activator precursor; t- PA; t-plasminogen activator; tPA Drug Category: Thrombolytic Agents Drug Type: Biotech; Approved Other Brand Names containing Anistreplase: Eminase (Wulfing Pharma GmbH); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Eminase (Wulfing Pharma GmbH): Powder, for solution Intravenous Chemical IUPAC Name: Human tissue plasminogen activator Chemical Formula: C2569H3928N746O781S40 Anistreplase on Wikipedia: https://en.wikipedia.org/wiki/Anistreplase Organisms Affected: Humans and other mammals